Investigative Subpoena for Fifteen Patient Files

Issue: The standard for enforcing an administrative investigative subpoena before formal charges.

Analysis: Administrative agencies have statutory authority to investigate complaints and to issue subpoenas in aid of that authority. At the investigative stage, the agency generally does not need probable cause or a formal complaint. The court's role is limited: it asks whether the subpoena is within the agency's authority, whether the requests are relevant and not unduly burdensome, and whether the agency is acting in good faith. A single billing complaint can justify looking at a sample of files from the same period to see whether the error was isolated or a pattern. Fifteen files may be broader than necessary, but the remedy is usually narrowing, not quashing entirely. The Board's chair signed the subpoena, which supports regularity.

Conclusion: The motion to quash is likely to fail on the probable-cause argument. Dr. Patel should comply with a narrowed request or negotiate the scope in good faith. Willful refusal can lead to contempt, default, or separate discipline. The direct email to the executive director is improper ex parte contact with a decision-maker; all communications should go to the investigator or the Board's counsel.

Issue: Whether patient confidentiality blocks a licensing-board subpoena.

Analysis: HIPAA permits disclosure to a health oversight agency for licensing and disciplinary activities without patient authorization. The Board is acting as a health oversight agency when it investigates a licensee. The disclosure must be limited to the minimum necessary for the investigation, and the Board must safeguard the records. Patient authorization is therefore not required. State confidentiality law may add protections, but it does not ordinarily prohibit a board investigation. As for notice, patients generally do not have a right to be notified at the investigative stage; requiring notice could compromise the investigation and is not a condition of the subpoena. The Board should nevertheless maintain the records separately, limit access to staff who need them, and avoid unnecessary disclosure in any public filing.

Conclusion: Dr. Patel cannot withhold the records on HIPAA grounds. He should produce them with a cover letter reserving objections to scope, not to the Board's authority. If he believes the request is overbroad, he should produce the Ortega file and negotiate the rest rather than refuse entirely.

Issue: The consequences of noncooperation and the procedural rights of a licensee under investigation.

Analysis: A licensee may consult counsel and may assert a constitutional privilege against compelled self-incrimination if testimony could expose him to criminal liability. Billing fraud may carry criminal exposure, so the privilege is real. But the privilege does not apply to the production of existing business records in the same way, and an administrative body may draw an adverse inference from silence in a civil or licensing proceeding. Refusing to appear at all can support a separate charge of failure to cooperate and can lead to contempt of the enforcing court. The Board can also proceed on the documentary record without his explanation.

Conclusion: Dr. Patel should appear with counsel, assert specific privileges question by question rather than refusing wholesale, and produce the records subject to a protective order. He should correct the billing error, refund any overpayment, and provide a written explanation. Cooperation and remediation are mitigating; blanket refusal is aggravating and may be treated as unprofessional conduct.